Eesti - eesti - Ravimiamet

alfasan nederland b.v. - kloprostenool - süstelahus - 0,25mg 1ml 20ml 1tk

Eesti - eesti - Ravimiamet

fatro s.p.a. - kloprostenool - süstelahus - 0,075mg 1ml 100ml 1tk; 0,075mg 1ml 10ml 1tk; 0,075mg 1ml 20ml 1tk

Eesti - eesti - Ravimiamet

kepro b.v. - kloprostenool - süstelahus - 0,25mg 1ml 20ml 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - radionukliidi pildistamine - diagnostilised radiofarmatseutilised ühendid - see ravim on mõeldud ainult diagnostiliseks kasutamiseks. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.